KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) EBITDA: 2017-2024

Historic EBITDA for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to -$44.1 million.

  • Aquestive Therapeutics' EBITDA fell 34.21% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$69.0 million, marking a year-over-year decrease of 96.00%. This contributed to the annual value of -$44.1 million for FY2024, which is 460.83% down from last year.
  • According to the latest figures from FY2024, Aquestive Therapeutics' EBITDA is -$44.1 million, which was down 460.83% from -$7.9 million recorded in FY2023.
  • Over the past 5 years, Aquestive Therapeutics' EBITDA peaked at -$7.9 million during FY2023, and registered a low of -$70.5 million during FY2021.
  • Over the past 3 years, Aquestive Therapeutics' median EBITDA value was -$44.1 million (recorded in 2024), while the average stood at -$35.5 million.
  • As far as peak fluctuations go, Aquestive Therapeutics' EBITDA surged by 85.54% in 2023, and later plummeted by 460.83% in 2024.
  • Yearly analysis of 5 years shows Aquestive Therapeutics' EBITDA stood at -$55.8 million in 2020, then fell by 26.45% to -$70.5 million in 2021, then rose by 22.87% to -$54.4 million in 2022, then soared by 85.54% to -$7.9 million in 2023, then plummeted by 460.83% to -$44.1 million in 2024.